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1. 
CONTROLLING CALCUM COMPOUND 
FORMATION IN BOCOMPATIBLE 
MATERALS FOR TISSUE REGENERATION 
AND REPAIR IN MAMMALS 
REFERENCE TO RELATED APPLICATION 
This application is a continuation-in-part application of 
PCT/US2010/048778 published as WO 2011/084.192 and 
filed on Sep. 14, 2010, claiming priority to U.S. application 
Ser. No. 12/683,280 filed Jan. 6, 2010, the entire disclosures 
of which are incorporated herein by reference. 
STATEMENT OF GOVERNMENT INTEREST 
This invention was made with Government support under 
Department of the Army contract W81XWH-08-1-7065. 
The Government may have certain rights in the invention. 
FIELD OF THE INVENTION 
This invention relates to biocompatible compositions for 
Surface and Subsurface implantation into mammals to facili 
tate tissue repair, regeneration, and proliferation. 
BACKGROUND OF THE INVENTION 
Bioactive glasses have been known for nearly 40 years 
and are considered osteoinductive and osteoconductive. 
They are currently used in a variety of bone repair and 
regeneration applications since these glasses react in a 
favorable way with the bodily fluids to form a calcium 
phosphate compound known as hydroxyapatite (HA) or 
carbonated hydroxyapatite (HCA). Since HA or HCA is the 
mineral component of natural bone, bioactive glasses form 
a strong chemical bond to human bone and over a period of 
time they are considered to be remodeled by the body to 
form new bone. 
Silicate-based glasses have been used as a basis for 
implantable compositions to Support the bonding, growth or 
genesis of bone by fostering a Supportive environment 
between the material and living, bone progenitor cells. It is 
widely recognized that Successful bioactive glasses include 
calcium and silica in order to foster the needed Supportive 
environment. Certain of these compositions are considered 
bioactive since they possess Surfaces capable of fostering a 
calcium phosphate layer which, in turn, promotes bone 
bonding to the material. For example, U.S. Pat. No. 5,204. 
106 discloses a composition termed 45S5 glass which is 
composed of NaO CaO POs SiO. 
Day et al. U.S. Pat. No. 6,709,744 describes biocompat 
ible materials for implantation which include borate-based 
glass or ceramic materials containing Na2O, CaO, P.O.s, and 
BO. A specific example is a glass containing about 22.9 wt 
% NaO, about 22.9 wt % CaO, about 5.6 wt % POs, and 
about 48.6 wt % B.O. These materials contain a high CaO 
concentration to facilitate the formation of hydroxyapatite 
when exposed to phosphorus-containing fluids in vivo or 
prior to implantation. 
There is a continuing need for a wider variety of biocom 
patible materials which promote rapid repair of mammalian 
tissue. 
SUMMARY OF THE INVENTION 
Briefly, therefore, the invention is directed to the repair 













time frame which is more rapid than is currently possible 
with bioactive silicate glasses and wherein the bioactive 
glasses react with the bodily fluids to form not only hydroxy 
apatite but also other calcium containing compounds which 
are biologically more preferred than the hydroxyapatite 
reaction product formed by the reaction of silicate glasses, 
and in certain applications to form Such other calcium 
containing compounds and affirmatively avoid forming 
hydroxyapatite. 
In another aspect, the invention is directed to a biocom 
patible composition for tissue repair or regeneration in 
mammals comprising one or more glass former compounds 
selected from the group consisting of BOs, POs, and SiO, 
director elements selected from the group consisting of Cu, 
Sr., Zn, Fe, Mn, Cr, V. Nb, Mo, W. Ba, Co, S, Al, Ti, Y. Mg, 
Si and/or Ni to promote in vivo calcium compound forma 
tion of calcium carbonate or other calcium compounds other 
than hydroxyapatite or amorphous calcium-containing mate 
rials other than hydroxyapatite; wherein upon direct appli 
cation of the biocompatible composition to a mammalian 
host, calcium carbonate or other calcium compounds other 
than hydroxyapatite or amorphous calcium-containing mate 
rials other than hydroxyapatite form upon bioreaction of the 
composition with bodily fluids. 
The invention is also directed to use of a composition 
comprising one or more glass former compounds selected 
from the group consisting of BOs, P.O.s, and SiO, and 
director elements selected from the group consisting of Cu, 
Sr., Zn, Fe, Mn, Cr, V. Nb, Mo, W. Ba, Co, S, Al, Ti, Y. Mg, 
Si and/or Ni to promote in vivo calcium compound forma 
tion of calcium carbonate or other calcium compounds other 
than hydroxyapatite or amorphous calcium-containing mate 
rials other than hydroxyapatite. 
In another aspect, the invention is directed to a method for 
forming a calcium compound in vivo in a mammal com 
prising implanting into the mammal a composition compris 
ing one or more glass former compounds selected from the 
group consisting of BO, P.O.s, and SiO, and director 
elements selected from the group consisting of Cu, Sr., Zn, 
Fe, Mn, Cr, V. Nb, Mo, W. Ba, Co, S, Al, Ti, Y. Mg, Si and/or 
Ni to promote in Vivo calcium compound formation of 
calcium carbonate or other calcium compounds other than 
hydroxyapatite or amorphous calcium-containing materials 
other than hydroxyapatite. 
Other objects and features of the invention are in part 
apparent and in part pointed out hereinafter. 
BRIEF DESCRIPTION OF THE FIGURES 
FIG. 1A shows chopped fibers 2 to 3 mm in length, 100 
to 300 um in diameter, used for making compositions of the 
invention. 
FIG. 1B shows a ceramic mold used to hold the fibers 
during the heat treatment. 
FIG. 1C is an example of a scaffold that weighs 70 mg and 
has dimensions of 7 mm in diameter and 2 mm thick. 
Scaffold porosity is 50+2%. 
FIG. 2 is a schematic showing Subcutaneous scaffold 
implant sites located on the back of a rat. 
FIG. 3 shows glass scaffolds according to the invention 
after six weeks implantation, except for the 13-93B3 scaf 
fold which was implanted for four weeks. 
FIG. 4 shows XRD patterns for randomly oriented scaf 
folds according to the invention after implantation. The 
respective lines have been displaced vertically for clarity. 
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FIG. 5 is an SEMBSE image of a cross sectioned Cu-3 
fiber scaffold that was implanted in the subcutaneous tissue 
of a rat for six weeks. 
FIG. 6 is an SEMBSE image of a cross sectioned CS fiber 
scaffold implanted subcutaneously in the back of a rat for six 
weeks. 
FIG. 7 is an SEMBSE image of a CS fiber implanted 
subcutaneously in the back of a rat for six weeks. 
FIG. 8 is an SEMBSE image of a cross sectioned CSZ 
fiber scaffold implanted subcutaneously in the back of a rat 
for six weeks. 
FIG. 9 is an SEMBSE image of a cross sectioned CSZ 
fiber scaffold implanted subcutaneously in the back of a rat 
for six weeks. 
FIG. 10 is an SEMBSE image of a cross sectioned CSZF 
fiber scaffold that was implanted subcutaneously in the back 
of a rat for six weeks. 
FIG. 11 is an EDS phase map of CSZF reacted fiber after 
six weeks in rat subcutaneous tissue. The SEMBSE image is 
shown bottom right of the image for reference. 
FIG. 12 is an SEMBSE image of a CSZF fiber implanted 
subcutaneously in the back of a rat for six weeks. 
FIG. 13 is a higher magnification photograph of the image 
in FIG. 12. 
FIGS. 14 and 15 are XRF patterns of compositions of the 
invention as-made and after implantation in vivo. 
FIG. 16 is an XRD pattern of a composition of the 
invention after one and two weeks in simulated bodily fluids. 
FIGS. 17-23 are micro Raman spectra of compositions of 
the invention as described in Example 7. 
FIG. 24 is a schematic presentation of how hydroxyapa 
tite formation is inhibited by the presence of six coordinated 
ions in aqueous environments. 
DESCRIPTION OF PREFERRED 
EMBODIMENTS 
The compositions of the invention employ one, two, or all 
three of BOs, SiO, or POs as glass former compounds. 
The compositions contain calcium and one or more elements 
which direct the formation of calcium-containing com 
pounds other than hydroxyapatite upon biodegradation of 
the compositions in vivo. The compositions are in the form 
of particulates, scaffold, mesh, or other form which is 
implantable or a form such as mesh or wrap which can be 
applied to the skin. The below discussion focuses on implan 
tation of the composition into a mammalian host; but in all 
significant aspects the invention is equally Suitable for other 
forms of direct application to the mammalian host such as a 
mesh or wrap applied over the skin. In other words, the 
invention is applicable to both Surface and Subsurface appli 
cation, provided the composition is exposed to the mamma 
lian hosts bodily fluids. 
All known bioactive glasses such as the well known 45S5 
and 13-93 react with the bodily fluids to form a hydroxy 
apatite type material. The term “bioactive' has come to refer 
specifically to materials which react with bodily fluids to 
form a calcium phosphate material Such as hydroxyapatite, 
non-stoichiometric hydroxyapatite, amorphous hydroxyapa 
tite, or carbonated hydroxyapatite. As used herein, the term 
“hydroxyapatite” designates these materials collectively 
unless stated otherwise. And while these are desirable mate 
rials for many in vivo applications because, for example, HA 
mimics bone, there are applications where it is desirable to 
form other types of calcium-containing materials when a 
bioactive glass reacts with bodily fluids. And there are 













hydroxyapatite materials. In accordance with this invention, 
the type of calcium-containing materials which forms when 
a bioactive glass reacts in vivo is controlled and directed, so 
that in some embodiments calcium-containing materials are 
formed in addition to HA, and in other embodiments cal 
cium-containing materials are formed instead of HA. This 
discovery offers the possibility of expanding the uses of 
bioactive glasses for bone replacement/repair applications 
and creating bioactive glasses which can react faster in the 
body and can convert to new bone more quickly than the 
presently available bioactive glasses. To distinguish from 
“bioactive' and “bioactivity” which have come to refer to 
HA formation, this application uses the terms “bioreactive' 
and “bioreactivity” to refer to reaction of the glass materials 
to form calcium-containing compounds which are not 
hydroxyapatite. 
A material that reacts with the bodily fluids to form calcite 
is resorbed by the body faster than a material that reacts to 
form hydroxyapatite (HA), especially stoichiometric crys 
talline HA. The solubility of hydroxyapatite is 5 mg/L at pH 
7.3, whereas the solubility of calcite is 6.6 mg/L. Calcite has 
also been found to be osteogenic (promotes bone growth), 
and when compared to hydroxyapatite is more effective in 
promoting bone growth. Therefore, a glass that forms cal 
cium carbonate, especially in the form of calcite—the most 
stable polymorph of calcium carbonate CaCO is expected 
to be resorbed faster by the body than a glass that forms 
hydroxyapatite (Caio (PO4)(OH)2). Because calcium car 
bonate is also osteogenic in that it promotes new bone 
formation, it promotes faster complete healing of bony 
defects. Calcium compounds other than hydroxyapatite 
include, for example, calcite, Vaterite (CaCO), calcium 
fluoride (CaF) tricalcium phosphate (TCP)(Ca(PO), tet 
racalcium phosphate (Ca(PO4)2O), oxyapatite, octacalcium 
phosphate (OCP)(Cash (PO)-5H2O, monetite (DCPA)(C- 
aHPO), brushite (DCPD)(CaHPO-2HO), and calcium 
hydroxide (Ca(OH). In some instances intermediate prod 
ucts which one might consider to not be compounds per se 
will form; so in this respect the invention involves forming 
calcium-containing materials (i.e., not necessarily com 
pounds), which are not hydroxyapatite. In a particular sys 
tem. Some of these may be metastable and transition com 
pounds. From solubility data for many of these compounds, 
one would be expected hydroxyapatite to precipitate early, 
because of its low solubility, relative to these other com 
pounds, upon introduction of Ca into a system containing P. 
O. H. and C, such as bodily fluids: 
TABLE 1. 
Material Chemical Formula Solubility (mg/L) 
Hydroxyapatite (HA) Cao(PO4)6(OH)2 5* 
Calcite CaCO 6.6 
Waterite CaCO 11 
Calcium Fluoride CaF, 16 
Tricalcium Phosphate (TCP) Ca(PO) 33: 
Octacalcium Phosphate (OCP) Cash (PO) 5H2O 39: 
Monetite (DCPA) CaHPO, 135* 
Brushite (DCPD) CaHPO 2H2O 1948 
Calcium Hydroxide Ca(OH)2 1600 
1Hydroxyapatite and Related Materials, Brown and Constantz, 1994 
2Handbook of Chemistry and Physics (90th edition) 2009-2010 
*Denotes a value calculated from solubility isotherms from FIG. 1 on page 74, pH = 7.3 
So if a source of calcium such as a Ca-containing biode 
gradable glass is implanted into an environment of P. O. and 
C, one would expect, as the Ca ions are released, to form 
hydroxyapatite sooner than calcite. However, if HA can be 
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prevented from forming then the next least soluble phase, 
calcite, would be expected to form. One would also expect 
these other compounds, if present in a particular system Such 
as bodily fluids, would dissociate into Ca, P etc. ions 
relatively sooner than hydroxyapatite. Furthermore, if cal 
cite dissociates into its ions sooner than does hydroxyapa 
tite, then such ions are available to perform a desired 
function in the body sooner. That function in the instance of 
bone repair is to grow hydroxyapatite at damaged bone sites. 
In other words, calcite facilitates growth of remodeled 
hydroxyapatite on a bone Substrate more quickly than 
hydroxyapatite does. It may therefore be advantageous for a 
bone repair implant to, upon implantation, form calcite 
instead of or in addition to hydroxyapatite. This invention 
leverages this concept by including director elements which 
essentially alter the normal hierarchy of calcium compound 
formation one would expect from the above solubility data 
as well as from the accepted maxim in the field that 
calcium-containing glasses in physiological fluids form 
hydroxyapatite. That is, the glass compositions of this 
invention are specifically formulated to biodegrade in physi 
ological fluids to form calcite and/or other calcium-contain 
ing compounds instead of, or in addition to, hydroxyapatite. 
In accordance with this invention, the elements which 
direct the formation of calcium-containing compounds other 
than hydroxyapatite upon biodegradation of the composi 
tions in vivo constitute minor amounts of Cu, Sr., Zn, Fe, Mn, 
Cr, V. Nb, Mo, W. Ba, Co, S, Al, Ti, Y. Mg, Si and/or Ni 
which are employed as a so-called “director elements’ to 
control the formation of HA and bias the in vivo calcium 
compound formation toward calcium carbonate or other 
calcium compounds other than hydroxyapatite or amor 
phous calcium-containing materials other than hydroxyapa 
tite. In one embodiment, the director element is Cu, Zn, Fe, 
Mn, Ba, Co, S. V. and/or Y either individually or in com 
bination; and in one preferred embodiment, the director 
element is Cu, Zn, Fe, Mn, Ba, Co, and/or S. Such as in one 
more particularly preferred embodiment where the director 
element is Zn and/or Fe, or one or more of Cu, Mn, Ba, Co, 
and/or S. Wherever this description refers to “director ele 
ment in the singular, it is to be understood to encompass 
one director element or two or more of the director elements. 
The invention in one aspect therefore involves use of a 
composition to promote in Vivo calcium formation of cal 
cium carbonate or other calcium compounds other than 
hydroxyapatite or amorphous calcium-containing materials 
other than hydroxyapatite, wherein the composition com 
prises one or more glass former compounds selected from 
the group consisting of BO, P.O.s, and SiO, and director 
elements selected from the group consisting of Cu, Sr., Zn, 
Fe, Mn, Cr, V. Nb, Mo, W. Ba, Co, S, Al, Ti, Y. Mg, Si and/or 
Ni. As is evident from the following description, the inven 
tion includes a method for forming a calcium compound in 
Vivo in a mammal comprising implanting into the mammal 
a composition comprising one or more glass former com 
pounds selected from the group consisting of BO, P.O.s, 
and SiO, and director elements selected from the group 
consisting of Cu, Sr., Zn, Fe, Mn, Cr, V. Nb, Mo, W. Ba, Co. 
S, Al, Ti, Y. Mg, Si and/or Ni to promote in vivo calcium 
compound formation of calcium carbonate or other calcium 
compounds or amorphous calcium-containing materials 
other than hydroxyapatite. 
Calcium-containing implantable bioactive glasses form 
hydroxyapatite upon reaction with bodily fluids according to 













In accordance with this invention, the glass composition is 
formulated to include the one or more director elements so 
as to produce desired calcium compounds or amorphous 
calcium-containing materials other than hydroxyapatite. In 
Some embodiments, these other calcium compounds and/or 
materials are formed entirely instead of hydroxyapatite. In 
other embodiments, a mixture of hydroxyapatite and one or 
more other calcium-based compounds is formed. In one 
preferred embodiment of the invention, the implantable 
glass composition is formulated to promote the formation of 
calcite upon reaction with bodily fluids in vivo. The major 
calcite formation reaction is as follows: 
Without being bound to a particular theory, it appears the 
atomic/ionic radius of a particular element has an impact on 
its efficacy as a director element alone or in combination 
with other elements in accordance with this invention. In 
particular, it is believed that an element with a relatively 
Smaller ionic radius Such as less than about 1 angstrom, or 
on the order of 0.8 angstroms or less, provides moderate to 
severe inhibition of hydroxyapatite formation, and biases the 
system toward calcite formation. 
The invention is useful in a wide variety of implantable 
applications and other tissue regenerative applications. 
Herein it will be described in the context of an implantable 
scaffold. In accordance with this invention, a director ele 
ment is incorporated into, for example, a scaffold of a 
biocompatible composition which is implantable at a mam 
mal’s Surface or Subsurface. The scaffold composition may 
optionally provide ions for biological use by the mammal, as 
described in co-pending application Ser. No. 12/683,280, the 
entire disclosure of which is incorporated by reference. The 
elements which function as director elements may also have 
other benefits, or separate trace elements may be incorpo 
rated as described in the co-pending application, indepen 
dent of the elements’ ability to function as director elements 
in accordance with this invention. These elements have 
beneficial effects such as an effect on endothelial cell migra 
tion which can be useful for blood vessel formation and have 
importance for tissue regeneration. In this way, these ele 
ments promote angiogenesis, which is a critical function in 
promoting tissue growth, such as in wound healing. This is 
in distinction from promoting osteoconductivity, which 
refers to providing bone growth factors to a site to promote 
bone growth. Angiogenesis, which involves increasing vas 
cularity, i.e., vessel growth, is distinct from osteoconductiv 
ity. However, certain of these director elements assist in 
promoting osteoconductivity as well. 
The scaffold of the invention comprises a scaffold body 
comprising a biocompatible material in the form of one or 
more of fibers, hollow fibers, tubes, ribbons, solid spheres, 
hollow spheres, particles, bonded particles, and combina 
tions thereof. In many of the more preferred embodiments, 
the form is loose or bonded fibers, or bonded particles. 
Generally speaking, a scaffold composed of multiple fibers 
and/or other of these elements has a weight of at least about 
10 milligrams, such as between about 10 milligrams and 
about 500 grams, for example between about 20 milligrams 
and about 2500 milligrams. The scaffold weight/dimensions 
depend upon the size of the wound/space being treated. The 
biocompatible material is borate-based, phosphate-based, 
and/or silicate-based and is glass, crystalline, or a combi 
nation of glass and crystalline. 
The biocompatible material fibers, spheres, or other 
shaped components in Some embodiments are in a loose 
assembly of nonbonded components. Alternatively, they are 
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bonded to each other, typically by heating, to define a 
scaffold body and provide a scaffold body compressive 
strength adequate for the particular application, for example 
of greater than 0.4 MPa for some applications. The desired 
compressive strength is selected so that the components are 
in no sense free flowing, and so that the scaffold body can 
be handled without disintegrating into the individual body 
components. The desired compressive strength is also 
selected to provide the strength that is required to remain 
integral after implantation, whether for repair of a load 
bearing body part or non-load-bearing part, or one Subject to 
impact or significant movement. In some preferred embodi 
ments, the compressive strength of the scaffold body is at 
least about 5 MPa, while in other embodiments where 
greater rigidity is required, the compressive strength is at 
least about 20 MPa, such as between about 20 and about 200 
MPa. 
The initial surface area of the scaffold varies widely 
depending on the scaffold morphology—for example, 
whether it is all fibers, the fiber dimensions, the particle size, 
etc. Moreover, the Surface area changes during biodegrada 
tion. Generally speaking, scaffolds of the fibrous morphol 
ogy have a surface area/bulk scaffold volume of between 
about 50 and about 1000 cm, such as between about 50 
and about 500 cm. One exemplary scaffold has a surface 
area/unit bulk volume of 134 cm', based on its dimensions 
of being a cylinder 7 mm in diameter and 2 mm high. The 
surface area of the starting glass fibers was 10.27 cm and 
the bulk volume of the cylinder was 7.7x10, cm. 
One or more director element compounds are incorpo 
rated into the implantable material in a concentration of at 
least about 0.05 wt %, or at least about 0.1 wt %. In most 
instances, the concentration is less than 10 wt %, or less than 
5 wt %, such as between about 0.05 and about 5 wt %, for 
example between about 0.1 and about 2.5 wt % (per com 
pound). A director element compound is an oxide or other 
compound of one of the director elements Cu, Sr., Zn, Fe, 
Mn, Cr, V. Nb, Mo, W. Ba, Co, S, Al, Ti, Y. Mg, Si and/or 
Ni, for example CuO, SrO, ZnO, or FeO. For example, Zn 
may be an oxide, carbonate, nitrate or other. While the 
director elements are described here and in the claims as 
director element compounds and described as various oxides 
by weight %, those skilled in the art understand that in the 
final glass or glass/crystalline composition, the oxide com 
pounds are dissociated, and the specific oxides, e.g., CuO. 
SrO, ZnO, or FeO are not separately identifiable or even 
necessarily separately present. Nonetheless, it is conven 
tional in the art to refer to the final composition as containing 
a given "% of the individual oxides, so that is done here. So 
from this perspective, the oxides herein are on an equivalent 
basis. 
Where the implantable biocompatible material is borate 
based or phosphate-based, the director element concentra 
tion is less than 5 wt %, and it may be higher and up to 10 
wt % where the biocompatible material is silicate-based. 
More than one of these director elements can be employed 
in a single composition. Also, certain of these elements may 
be present in greater amounts in that they are not being used 
as director elements in accordance with this invention. For 
example, a composition made of a biocompatible glass 
material which contains 0.4 wt % CuO and 15 wt % SrO 
contains Cu as a director element in accordance with this 
invention; and it contains Sr, but not as a director element in 
accordance with this invention. Such a material would 
indeed satisfy the requirement herein for a director element 













concentration between about 0.05 and 10 wt % by virtue of 
the materials Cu content, regardless of its undualifying Sr 
COntent. 
Where Cu is desired as the director element, the source of 
Cu to the glass or crystalline biocompatible material may be 
a copper oxide Such as CuO or CuO or other copper 
compounds such as copper nitrate or copper Sulfate, for 
example. In one embodiment, Cu is incorporated into the 
glass in a CuO concentration of at least about 0.05 wt %, or 
at least about 0.1 wt %. In most instances, the concentration 
is less than 10 wt %, or less than 5 wt %, such as between 
about 0.05 and about 5 wt %, for example between about 0.1 
and about 2.5 wt % 
Where Sr is desired as the director element, the source of 
Sr to the glass or crystalline biocompatible material may be 
an oxide such as SrO or other Sr compounds such as SrCO, 
for example. In one embodiment, Sr is incorporated into the 
glass in a SrO concentration of at least about 0.05 wt %, or 
at least about 0.1 wt %. In most instances, the concentration 
is less than 10 wt %, or less than 5 wt %, such as between 
about 0.05 and about 5 wt %, for example between about 0.1 
and about 2.5 wt % 
Where Zn is desired as the director element, the source of 
Zn to the glass or crystalline biocompatible material may be 
an oxide Such as ZnO or other Zn compounds such as 
Zn(PO4)-XH2O, for example. In one embodiment, Zn is 
incorporated into the glass in a ZnO concentration of at least 
about 0.05 wt %, or at least about 0.1 wt %. In most 
instances, the concentration is less than 10 wt %, or less than 
5 wt %, such as between about 0.05 and about 5 wt %, for 
example between about 0.1 and about 2.5 wt % 
Where Fe is desired as the director element, the source of 
Fe to the glass or crystalline biocompatible material may be 
an oxide Such as FeC), Fe-O, Fe2O, or other Fe compounds 
such as FeSO-7HO, for example. In one embodiment, Fe 
is incorporated into the glass in a Fe2O concentration of at 
least about 0.05 wt %, or at least about 0.1 wt %. In most 
instances, the concentration is less than 10 wt %, or less than 
5 wt %, such as between about 0.05 and about 5 wt %, for 
example between about 0.1 and about 2.5 wt %. 
Calcium is incorporated into the compositions of the 
invention to facilitate the formation of calcium carbonate 
(such as calcite) and optionally other calcium-containing 
compounds upon bioreaction of the composition with bodily 
fluids after implantation into a mammalian host. The CaO 
concentration of the composition is between about 2.5 and 
about 50 wt %, for example between about 5 and about 40 
wt %. In a preferred embodiment, the CaO concentration is 
between about 12 and about 25 wt.%. In the composition, the 
oxide compounds are dissociated, and the specific CaO or 
other oxides are not typically not separately identifiable or 
even necessarily separately present. Nonetheless, it is con 
ventional in the art to refer to the final composition as 
containing a given 9% of the individual oxides, so that is done 
here. This CaO concentration is typically provided in the 
form of a Ca compound such as CaO or CaCO, Ca(NO), 
Ca(OH) and others. 
The director element and biocompatible composition are 
carefully selected and formulated to provide a specifically 
timed release of director element based on flow of blood or 
other physiological fluids through the scaffold as the bio 
compatible composition biodegrades in the mammalian 
host. The director element is an integral component of the 
biocompatible composition and is chemically dissolved in 
the material. This is in sharp contrast to being in the form of 
a coating on the glass or being simply adsorbed onto the 
material as, for example, adsorbed onto a water insoluble 
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implantable compound. Since the director element is chemi 
cally dissolved in the glass material, it is released into the 
host mammal incrementally as the glass biodegrades, and 
over that same period during which the glass biodegrades. In 
contrast, a coating or adsorbed material is released more 
quickly, and its release cannot be controlled by controlling 
the composition of the overall glass material. In one embodi 
ment, the director element is generally macro-homoge 
neously present in the biocompatible composition to facili 
tate release over the entire degradation life of the 
composition. As blood and or other fluids flow through the 
scaffold and the scaffold biodegrades in the host mammal, 
the director element is released to provide its advantageous 
angiogenic effect over time in promoting benefits to the host 
in the area of the implantation. So, for example, as the 
borate-based, phosphate-based, or silicate-based composi 
tion biodegrades, it releases director element to promote 
angiogenesis or some other desirable biological function. 
The glass formers in certain embodiments of the invention 
are concentration balanced to impart the desired biodegrad 
ability. For example, in the B3-CSZ composition of below 
Example 1, the concentrations of the glass formers borate, 
silicate, and phosphate are balanced to 51.2 wt %, 0 wt %, 
and 3.86 wt %, respectively, and in the CSZF composition 
to 50.88 wt %, 0 wt %, and 3.84 wt %, respectively, with 
respect to themselves and with respect to the other compo 
nents in the material NaO, CaO, and KO. Balancing in this 
regard encompasses balancing the concentration of one glass 
former with other components, such as with those glasses 
contain borate and other components, but no phosphate or 
silicate. 
In many preferred embodiments of the scaffold, the con 
centrations of glass formers are balanced such that at least 
about 20 wt % of the biocompatible material biodegrades 
within six weeks of implantation in its mammalian host. For 
example, the concentrations of glass formers are balanced 
such that at least about 20 wt % of the biocompatible 
material biodegrades within six weeks of implantation in a 
Fisher 344 rat having an age between 9 and 11 weeks and a 
weight between 200 and 300 grams. In accord with this 
measure, the testing is performed on rats with a standard 
deviation of 25% (relative) of the biocompatible material 
and a population size of 10. In other words, when 10 of these 
scaffolds are implanted into the Subcutaneous sites of rats, 
on average at least 20 wt % of the scaffolds material 
biodegrades within six weeks; and in at least 68% of rats at 
least 15 wt % of the scaffold biodegrades; and in at least 90% 
of rats at least 10 wt % of the scaffold degrades. Biodegrad 
ing in most instances manifests itself as scaffold weight loss, 
but can also manifest itself as another reaction of the scaffold 
material involving a change of composition which results in 
release of director element. 
Similarly, in another aspect, the concentrations of glass 
formers are balanced such that at least about 20 wt % of the 
director element concentration in the scaffold is released 
from the scaffold within six weeks of implantation in its 
mammalian host. For example, the concentrations of glass 
formers are balanced such that at least about 20 wt % of the 
director element concentration in the scaffold is released 
from the scaffold into the host within six weeks of implan 
tation in a Fisher 344 rat having an age between 9 and 11 
weeks and a weight between 200 and 300 grams. In accord 
with this measure, the testing is performed on rats with a 
standard deviation of 25% (relative) of the biocompatible 
material and a population size of 10. In other words, when 
10 of these scaffolds are implanted into the subcutaneous 













director element concentration is released within six weeks; 
and in at least 68% of rats at least 15 wt % of the scaffolds 
director element concentration is released; and in at least 
90% of rats at least 10 wt % of the scaffolds director 
element concentration is released. 
On the other hand, the scaffold does not biodegrade so 
quickly that it does not provide its healing benefits for 
sufficient time. For example, at least 50 wt % of the scaffold 
material remains for at least two weeks and does not 
biodegrade within two weeks. That is, the concentrations of 
glass formers are balanced such that at least about 50 wt % 
of the biocompatible material remains for at least two weeks 
after implantation in a Fisher 344 rat having an age between 
9 and 11 weeks and a weight between 200 and 300 grams. 
In accord with this measure, the testing is performed on rats 
with a standard deviation of 25% (relative) of the biocom 
patible material and a population size of 10. In other words, 
when 10 of these scaffolds are implanted into the rats, on 
average at least 50 wt % of the scaffolds material does not 
biodegrade within two weeks; and in at least 68% of rats at 
least 37.5 wt % of the scaffold does not biodegrade within 
two weeks; and in at least 90% of rats at least 25 wt % of 
the scaffold does not biodegrade within two weeks. 
Moreover, in these embodiments, at least 50 wt % of the 
scaffold director element concentration remains for at least 
two weeks. That is, the concentrations of glass formers are 
balanced such that at least about 50 wt % of the director 
element remains for at least two weeks after implantation in 
a Fisher 344 rat having an age between 9 and 11 weeks and 
a weight between 200 and 300 grams. In accord with this 
measure, the testing is performed on rats with a standard 
deviation of 25% (relative) of the biocompatible material 
and a population size of 10. In other words, when 10 of these 
scaffolds are implanted into the rats, on average at least 50 
wt % of the scaffolds director element concentration 
remains for at least two weeks; and in at least 68% of rats 
at least 37.5 wt % of the scaffolds director element con 
centration remains for at least two weeks; and in at least 90% 
of rats at least 25 wt % of the scaffolds director element 
concentration remains for at least two weeks. 
As noted above, the biocompatible materials, whether in 
the form of scaffolds or other shapes, biodegrade in physi 
ological fluids. However, in comparison to articles charac 
terized as “water soluble' which dissolve relatively rapidly 
(over a period of, e.g., three weeks or less) in aqueous 
solutions, the biocompatible materials of the invention are 
not water soluble, that is, they are resistant to rapid water 
solubility. For example, scaffolds made from them having a 
Surface area and size of practical application for use as an 
implantable scaffold do not completely dissolve in a less 
than several weeks (e.g., six weeks) at 37°C. in an aqueous 
phosphate solution or an aqueous Solution with a miscible 
Solvent Such as methanol, ethanol, isopropanol, acetone, 
ethers or the like. As understood in the art, materials which 
are “water soluble' are subject to relatively rapid solubility: 
and materials which are “water insoluble' are either entirely 
insoluble in water, or are at least only dissolvable with 
difficulty. Generally speaking the scaffold materials are not 
water insoluble and are not water soluble under this char 
acterization; rather, they are of intermediate water solubility. 
In one embodiment the director element is incorporated 
into aborate-based glass material containing the following, 
approximately, with all percentages herein being by weight, 
unless stated otherwise: 
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B2O3 40 to 8O 
Na2O O to 25 
Li2O O to 25 
KO O to 25 
Rb2O O to 25 
CaO 2.5 to 50 (or 45) 
MgO O to 25 
SO O to 40 
BaO O to SO 
Li2O + NaO + KO + Rb2O O to 50 cumulative 
MgO + SrO + BaO + CaO O to 50 cumulative 
P-Os O to 10 
SiO, O to 18 
Al2O3 O to 3 
O to 4 
transition metal elements O to 10 cumulative. 
The concentrations of KO and MgO in certain of these 
embodiments are each from about 1 to about 25 wt %. In 
most embodiments, the one or more of LiO, NaO, KO. 
and RbC) is present in a cumulative concentration between 
about 1 and about 50 wt %, such as between about 5 and 
about 20 wt %; and the one or more of MgO, SrO. BaO, and 
CaO is present in a cumulative concentration between about 
1 and about 50 wt %, such as between about 5 and about 40 
wt %. Where Cu is the director element, this composition 
further contains at least about 0.05 wt %, or at least about 0.1 
wt %, such as between about 0.05 and about 5 wt %, for 
example between about 0.1 and about 2.5 wt % Cu.O. The 
transition metal elements are those elements where the 
d-band contains less than its maximum number of ten 
electrons per atom, and includes, among others, Co and Ni. 
In fact, certain of the director elements used in accordance 
with this invention Such as Zn and Fe are transition metals. 
So in formulations where the director element concentration 
of these director elements is stated to be in a particular range 
such as between about 0.1 and about 2.5 wt %, of course the 
director element concentration is in that range regardless of 
the fact that transition elements may be among the director 
elements, and if Zn and Fe are present in an amount greater 
than 2.5 wt %, they are not director elements. 
In most embodiments the biocompatible material consists 
only or essentially of components meeting these composi 
tional requirements or other narrower descriptions herein. 
But generally speaking, for some embodiments other mate 
rials not meeting these descriptions may be incorporated into 
the scaffolds. 
It can therefore be appreciated that in addition to the 
director element, the borate-based biocompatible materials 
in certain embodiments include 40 to 80 wt % BO, or 50 
to 80 wt % BO, or even the narrower BO ranges 
described herein, in combination with 1 to 25 wt % Nao. 1 
to 25% KO, 1 to 40 wt % CaO, 1 to 25 wt % MgO, and 1 
to 10 wt % POs. Or the component materials may contain 
40 to 80 wt % BO, 1 to 25 wt % LiO, and 5 to 40 wt % 
CaO. Or they may contain 40 to 80 wt % BO, 1 to 25 wt 
% NaO, and 1 to 40 wt % CaO. Or they may contain 40 to 
80 wt % BO, 1 to 25 wt % NaO, and 1 to 40 wt % BaO. 
Or they may contain 40 to 80 wt % BO, 1 to 25 wt % LiO, 
and 1 to 25 wt % MgO. Or they may contain 40 to 80 wt % 
BO, 1 to 25 wt % LiO, and 1 to 40 wt % BaC). 
While the biocompatible materials hereinabove and here 
inbelow are described as containing various oxides by 
weight%, those skilled in the art understand that in the final 
glass or glass/crystalline composition, the oxide compounds 
are dissociated, and the specific oxides, e.g., B.O., SiO, 
POs, etc. are not separately identifiable or even necessarily 













to refer to the final composition as containing a given "% of 
the individual oxides, so that is done here. So from this 
perspective, the compositions herein are on an equivalent 
basis. 
The biocompatible materials of the invention containing 
the director element in certain preferred versions are borate 
based in that they contain between about 40 and about 80 wt 
% BO, such as between about 50 and about 80 wt % B.O. 
Borate-based materials have several important advantages 
for biological use such as their ease of preparation, ability to 
be made into glass particulates, microspheres or fibers at 
relatively low temperatures without crystallization, their 
angiogenicity and bacteriostaticity, and, particularly, their 
biocompatibility. The borate-based materials disclosed 
herein, compared to silicate-based materials, have signifi 
cantly faster—e.g., 3 to 10 times—reaction rates, lower 
melting temperatures, resistance to crystallization, and in 
certain instances the absence of silica, which only slowly 
degrades in the body. So while certain embodiments employ 
up to about 18 wt % SiO in many other preferred embodi 
ments herein, the materials are silica-free, containing less 
than 0.1 wt % silica or even no silica. Upon reaction in vitro, 
interior segments of the borate-based fibers become exca 
vated and in fact hollow as interior borate material biode 
grades. Upon reaction in vivo, interior segments of borate 
based fibers become excavated as interior borate material 
biodegrades and is filled with soft tissue, including blood 
vessels, bodily fluids, and the like. Accordingly, in vivo the 
fibers after bioreaction have tubular and hollow aspects 
which are filled with soft tissue, as the initially hollow 
interior of the fiber is replaced with soft tissue including 
blood vessels, bodily fluids, and the like. The borate mate 
rials described herein also release boron in vivo as they react 
with the bodily fluids. 
In one preferred embodiment, the material contains 
between about 50 and about 80 wt % B.O.; between about 
5 and about 20 wt % alkali oxide component selected from 
the group consisting of Li2O, NaO, K2O, Rb2O, and 
combinations thereof, and between about 5 and about 40% 
alkaline earth component selected from the group consisting 
of MgO, SrO. BaO, and combinations thereof. Lanthanides 
are specifically and strictly excluded from certain preferred 
embodiments. In some embodiments the biocompatible 
material consists essentially of between about 50 and about 
80 wt % B.O.; between about 5 and about 20 wt % alkali 
oxide component selected from the group consisting of 
LiO, NaO, KO, Rb O, and combinations thereof; 
between about 5 and about 40 wt % alkaline earth compo 
nent selected from the group consisting of MgO, SrO, BaO. 
and combinations thereof, and between about 0.05 and 5 wt 
% director element. 
In certain embodiments of the invention, the biocompat 
ible material is selected to include at least two of the alkali 
oxides LiO, NaO, KO, and/or RbO in a cumulative 
concentration of between about 5 and about 25 wt %, such 
as between about 8 and 20 wt %. It has been discovered to 
be advantageous to include two or more such alkali com 
pounds in order to reduce the tendency for crystallization, 
which ultimately improves the workability and manufactur 
ability of the glasses, which can be important to making 
scaffolds. Using more than one type of alkali (i.e., mixed 
alkali) can reduce the cost of a glass, modify its reaction rate 
with bodily fluids, and provide additional elements benefi 
cial to tissue growth and regeneration. 
A further feature of certain embodiments is that the 
cumulative concentration of the alkaline earth oxides from 
the group consisting of MgO, SrO. BaO, CaO, and combi 
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nations thereof is in the range of 1 to about 50 wt %, such 
as in the range of 1 to 30 wt %, or even about 8 to 25 wt %. 
Certain of these embodiments contain two or more such 
alkaline earth oxides in a range of 1 to 45 wt % cumulatively, 
such as in the range of 5 to 25 wt %. If SrO is present in a 
concentration which yields a Sr concentration above 10 wt 
%, it does not qualify as a director element in accordance 
with this invention. 
These embodiments into which the director element may 
be incorporated and which employ mixed alkali oxide 
contents contain BOs from about 40 to about 80 wt %. 
Certain of these embodiments consist essentially of BO 
from about 40 to about 80 wt %, mixed alkali oxides selected 
from the group consisting of LiO, NaO, KO, and RbC), 
and one of MgO, SrO. BaO, or CaO, plus the Cu containing 
compound. Other embodiments consist essentially of BO 
from about 40 to about 80 wt %, two or more alkali oxides 
selected from the group consisting of LiO, Na2O, K2O, and 
Rb2O, and two or more alkaline earth oxides from the group 
consisting of MgO, SrO. BaO, and CaO, plus the Cu 
containing compound. For example, the first four composi 
tions in the table in Example 1 consist essentially of BO 
from about 40 to about 80 wt %, two or more mixed alkali 
oxides selected from the group consisting of Li2O, NaO. 
KO, and RbC) in a cumulative wt % between 5 and 25%, 
and two or more from among MgO, SrO. BaO, and CaO in 
a cumulative wt % between 8 and 25%. Other embodiments 
optionally include one or more of POs, SiO, Al-O. F. and 
transition metal elements. 
The invention includes incorporating director element 
into biocompatible materials with an especially high BO 
composition, namely, from about 60 to about 82 wt %, still 
more preferably from about 70 to about 80 wt %. These 
embodiments employ an alkali oxide selected from the 
group consisting of LiO, NaO, K2O, Rb2O, and combi 
nations thereof cumulatively from about 1 to about 50 wt %, 
such as from about 5 to about 25 wt %, and even from about 
8 to about 20 wt %; and even optionally two or more such 
oxides cumulatively in this range. They also employ alkaline 
earth oxides from group consisting of MgO, SrO, BaO, CaO. 
and combinations thereof in the range of about 1 to about 50 
wt %, such as in the range of 1 to 30 wt %, or even about 
8 to 25 wt %, and even two or more such oxides cumula 
tively in this range 
The invention also encompasses a biocompatible compo 
sition for implantation into a mammal to facilitate vessel 
growth in repair, regeneration, and/or proliferation of bodily 
tissue, wherein the biocompatible material is phosphate 
based or silicate-based and is at least partially dissolvable in 
mammalian bodily fluids, and the director element is incor 
porated into the biocompatible material in a concentration as 
described above. In these embodiments, POs and/or SiO, 
are glass formers and constitute about 20 to about 65 wt % 
POs or about 20 to about 60 wt % SiO. These materials 


























example, one or more of LiO, Na2O, KO, RbC), Cs-O, or 
a mixture thereof in a concentration of about 8 wt % to about 
55 wt %, such as about 10 to about 52 wt %. These 
phosphate- and silicate-based glasses also contain a calcium 
component, one of CaO, CaF, or mixtures thereof. For 
example, many of these glasses contain from about 5 to 
about 40 wt % of CaO or CaF, or mixtures thereof, such as 
about 10 to about 30 wt % of CaO or CaF, or mixtures 
thereof, or about 10 to about 15 wt % of CaO or CaF, or 
mixtures thereof. Accordingly, one of these embodiments 
contains about 20 to about 65 wt % POs, and one or more 
of LiO, NaO, KO, Rb,O, Cs-O, or a mixture thereof in a 
concentration of about 8 wt % to about 55 wt %, and a 
calcium component of in a concentration of about 5 to about 
40 wt % of CaO or CaF, and Cu in a concentration of about 
0.05 to about 5 wt %, such as between about 0.1 and about 
2.5 wt %. Another embodiment contains about 20 to about 
65 wt % P.O.s, and one or more of LiO, NaO, KO, Rb O. 
Cs-O, or a mixture thereof in a concentration of about 10 wt 
% to about 52 wt %, a calcium component of CaO or CaF 
or mixtures thereof in a concentration of about 5 wt % to 
about 40 wt % of CaO or CaF2 or mixtures thereof, and Cu 
in a concentration of about 0.05 to about 5 wt %, such as 
between about 0.1 and about 2.5 wt %. Another embodiment 
contains about 20 to about 65 wt % POs, and one or more 
of LiO, NaO, KO, Rb,O, Cs-O, or a mixture thereof in a 
concentration of about 8 wt % to about 55 wt %, a calcium 
component of CaO or CaF2 or mixtures thereof in a con 
centration of about 10 to about 30 wt % of CaO or CaF, or 
mixtures thereof, and Cu in a concentration of about 0.05 to 
about 5 wt %, such as between about 0.1 and about 2.5 wt 
%. Another of these embodiments contains about 20 to about 
60 wt % SiO, and one or more of LiO, NaO, K2O, Rb2O, 
Cs-O, or a mixture thereof in a concentration of about 8 wit 
% to about 55 wt %, a calcium component of CaO in a 
concentration of about 5 to about 40 wt % of CaO or CaF, 
and Cu in a concentration of about 0.05 to about 5 wt %, 
such as between about 0.1 and about 2.5 wt %. Another 
embodiment contains about 20 to about 60 wt % SiO, and 
one or more of LiO, NaO, KO, Rb2O, Cs-O, or a mixture 
thereof in a concentration of about 10 wt % to about 52 wit 
%, a calcium component of CaO or CaFor mixtures thereof 
in a concentration of about 5 wt % to about 40 wt % of CaO 
or CaF2 or mixtures thereof, and Cu in a concentration of 
about 0.05 to about 5 wt %, such as between about 0.1 and 
about 2.5 wt %. Another embodiment contains about 20 to 
about 60 wt % SiO, and one or more of LiO, NaO, KO. 
Rb2O, CSO, or a mixture thereof in a concentration of about 
8 wt % to about 55 wt %, a calcium component of CaO or 
CaF, or mixtures thereof in a concentration of about 10 to 
about 30 wt % of CaO or CaF2 or mixtures thereof, and Cu 
in a concentration of about 0.05 to about 5 wt %, such as 
between about 0.1 and about 2.5 wt %. In certain of these 
embodiments, CaF2 is strictly avoided and the calcium 
component is CaO. 
Examples of silicate-based biocompatible material con 
taining director elements in accordance with this invention 
are as follows: 
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Examples of phosphate-based biocompatible glass con 
taining director elements in accordance with this invention 
are as follows: 
Glass 
ID Na2O KO CaO MgO B.O. POs Li2O SrO CuO 
P-1 3.8 S.8 27.5 2.5 O.O 6O.O O.O. O.O. O.4 
P-2 9.2 9.3 27.5 O.O. O.O S3.5 O.O. O.O. O.S 
P-3 7.8 11.8 17.O 76 O.O SS.2, O.O. O.O. O.6 
P-4 7.8 11.8 17.O 76 O.O SS.2, O.O. O.O. O.6 
P-5 6.6 89 21.9 O.O 41 58.O O.O. O.O. O.S 
P-6 1O.S O.O 230 O.O 4.O 611 11 O.O O.3 
P-7 8.0 3.7 1.5 O.O 1.8 78.1 O.O 6.7 O.2 
These phosphate-based formulations demonstrate situa 
tions where it is advantageous to include at least two of the 
alkali oxides LiO, NaO, K2O, and/or Rb2O in a cumulative 
concentration of between about 5 and about 25 wt %, such 
as between about 8 and 20 wt %. As noted above, it has been 
discovered to be advantageous to include two or more Such 
alkali compounds in order to reduce the tendency for crys 
tallization, which ultimately improves the workability and 
manufacturability of the glasses, which can be important to 
making scaffolds. Using more than one type of alkali (i.e., 
mixed alkali) can reduce the cost of a glass, modify its 
reaction rate with bodily fluids, and provide additional 
elements beneficial to tissue growth and regeneration. In one 
embodiment Na and K are incorporated into the glass and 
upon dissolution the glass releases both of these necessary 
elements to the host’s bodily fluids. 
A further feature of these phosphate-based embodiments 
is that the cumulative concentration of the alkaline earth 
oxides from the group consisting of MgO, SrO, BaO, CaO. 
and combinations thereof is in the range of 1 to about 50 wt 
%, such as in the range of 1 to 30 wt %, or even about 8 to 
25 wt %. Certain of these embodiments contain two or more 
such alkaline earth oxides in a range of 1 to 45 wt % 
cumulatively, such as in the range of 5 to 25 wt %. 
The biocompatible materials of the invention are in the 
form of solid fibers, hollow fibers, ribbons, solid spheres, 
hollow spheres, particles, and combinations thereof. In an 
especially preferred embodiment for many applications, the 
composition is in the form of a scaffold body which includes 
fibers, and in certain such embodiments it is a scaffold body 
which consists essentially of components which are fibers. 
The fibers have an aspect ratio of at least 2:1 length: 
transverse dimension (e.g., diameter), and more typically at 
least 5:1. Such as greater than 10:1. In certain embodiments 
of the invention, the scaffold body components are primarily 
one form, such as fibers, in combination with a minor 
constituent of a second form from the foregoing options, 
Such as microspheres. 
There is also an option with this invention of employing 
distinct component compositions to strategically impart cer 
tain properties. For example, the composition in some 
embodiments is “blended in that it employs 10 to 90 wt % 
of components having one composition selected from the 
above, and 10 to 90 wt % of components of a different 
composition. Or even more than two Such types of compo 
nents may be employed. That is, the material may contain at 
least 10 wt % of components comprising a first component 
material within the contemplated compositions and at least 
10 wt % of components comprising a second component 
material, wherein the first and second component materials 
have compositions measurably distinct from each other. And 













contain the director element, or that the director element 
may be present in both materials in different amounts. This 
permits the selection of, for example, faster reacting fibers in 
combination with slower reacting fibers; or the selection of 
Ca-containing fibers with Ca-free fibers. One can therefore 
select standard composition components and combine them 
with non-standard composition components to effectively 
customize or dope the scaffold for the application presented, 
or for the host’s particular needs. Alternatively, hollow 
spheres containing a growth factor or drug for delivery to the 
host can be incorporated with other structural components, 
such as fibers. 
In one embodiment the director element is incorporated 
into the materials and a scaffold is formed to have a porosity 
which is selected to provide fluid flow into the scaffold to 
facilitate uptake of bodily fluids, while maintaining suffi 
cient strength for handling and implantation. The porosity is 
between about 15 vol % and about 90 vol%. There are 
different levels of porosity, for example between about 15 
and about 30 vol%, or between about 30 and about 60 vol 
%, or between about 60 and about 90%, which are preferred 
for different applications. Porosity depends on or is con 
trolled by many factors such as fiber orientation, shape of 
particles or microspheres, and the thermal treatment (time/ 
temperature) used to bond the elements together. Indepen 
dent of this bulk porosity, interconnectivity is also important 
in embodiments of the invention which are in the form of 
scaffolds. Because tissue repair is strongly influenced by the 
flow of bodily fluids into the scaffold, it is preferred to have 
a high level of interconnectivity of pores within the scaffold, 
and a low level of closed pores. That is, it is important that 
most pores be connected to other pores, and that there is a 
director indirect path from most pores to the exterior surface 
of the scaffold. In certain embodiments, at least about 80 vol 
%, such as at least about 90%, of the pore volume of the 
scaffold is directly or indirectly through other pores acces 
sible from the scaffold exterior, and therefore accessible to 
bodily fluids. The scaffold has interconnectivity of at least 
about 75%, preferably at least about 85%, by which it is 
meant that at least 75% or 85% by volume of the pores is 
interconnected. 
The method of making the biocompatible materials is not 
narrowly critical to the invention. By way of example, in 
preparing the biocompatible materials, individual analytical 
reagent grade components are weighed, mixed thoroughly, 
and melted in a platinum crucible at temperatures between 
1000 to about 1500° C., depending upon composition for 
approximately one to four hrs. The melt is then quenched, 
for example, on a steel or copper plate to form glass that can 
be ground into particulates of a desired size. The particulates 
can be spheroidized to form microspheres of a chosen 
diameter. The material of certain preferred compositions 
when in the form of a melt can easily be formed into fibers. 
If fibers of the borate glass are made, they can either be 
pulled by hand directly from the melt or pulled through 
bushing by a rotating drum. 
The components can be self-bonded to form three dimen 
sional scaffolds by simply heating an assemblage of par 
ticulates in a furnace and allowing the fibers/particles/ 
spheres to soften and bond to each other. After the allotted 
time at temperature, the construct is removed from the 
furnace and cooled to room temperature. Many prior bio 
compatible glasses, such as 45S5, are difficult to self bond 
due to crystallization of the glass. Therefore the self-bonding 
ability of borate glasses is a distinct advantage over other 
biocompatible materials currently in use. 
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In one embodiment the invention is a scaffold adapted for 
soft tissue growth which is prepared from fibers which are 
aligned so that a majority of the fibers are substantially 
aligned in a parallel direction. The scaffold is prepared by 
placing and orienting fibers in a unidirectional manner in a 
mold. The fibers in the mold are heated to a temperature 
where the fibers soften and bond together. In one preferred 
embodiment, the fibers are self bonded in the sense that no 
adhesive or other external bonding agent is used for bond 
ing. An alternative embodiment employs a biocompatible 
agent or adhesive to facilitate bonding, such that the fibers 
are not self bonded, at least in part. Upon cooling, the 
assemblage of bonded fibers is Sufficiently rigid and strong 
that the assemblage can be removed from the mold and 
handled. The scaffold is sufficiently rigid that it can be 
implanted into a mammal where it facilitates the repair and 
regeneration of hard tissue Such as bone (including cortical 
and cancellous) or soft tissue such as muscle, cartilage, skin, 
organ, or other hard or Soft tissue. 
The orientation of the fibers in a lengthwise direction in 
the self-bonded scaffold provides lengthwise channels (or 
connected pores) among the fibers, which channels provide 
for uptake into the scaffold of stem cells, growth factors, 
medicines, proteins, red blood cells and other physiological 
materials and components carried in bodily fluids. The fibers 
are arranged to define channels within the scaffold which 
facilitate fluid flow into and lengthwise within the scaffold 
from one end to the other end. The orientation also provides 
for channels in a transverse direction generally perpendicu 
lar to the lengthwise direction of the oriented fibers, to 
facilitate uptake of fluids from the outer surface of the 
interior or core of the scaffold. These longitudinal and 
transverse channels exert significant capillary forces on a 
liquid which cause the liquid to be drawn into the scaffold. 
This capillary action facilitates the distribution of these 
fluids and components relatively uniformly throughout the 
scaffold and enables fluids to flow from one end of the 
scaffold to the other or to enter the scaffold from its surface 
and draw the liquid inward to the center and ends of the 
scaffold. 
The invention in one embodiment employs fibers having 
a diameter, prior to molding and softening, between about 20 
and about 5000 microns, such as between about 50 and 
about 5000 microns. In one embodiment the scaffold is 
prepared from fibers having diameters between about 100 
and about 450 microns, such as between about 100 and 
about 300 microns. In an alternative embodiment, the scaf 
fold is prepared from fibers having diameters up to about 
3000 or 5000 microns (3 to 5 mm), which can be deemed 
more akin to rods than fibers in some contexts, but for 
purposes of the discussion of this invention fall within the 
definition of “fibers. 
In one aspect of the invention employing co-aligned 
fibers, at least about 75 or 85% by volume of the fibers in the 
scaffold are longitudinally co-aligned. In this regard the 
fibers are co-aligned longitudinally, where “co-aligned lon 
gitudinally and the like phrases (e.g., "in lengthwise co 
alignment') as applied to a group of adjacent, bundled, or 
joined fibers in this application means that the alignment of 
each fiber in the group at any one place along at least about 
75% of its length does not deviate more than about 25 
degrees from parallel to the central axis of the scaffold. For 
illustration, an example of co-alignment is the alignment of 
individual wires or filaments in a multistrand/filament cable. 
In one preferred embodiment, each fiber in the group at any 
one place along at least about 75% of its length does not 













central axis of the scaffold. In another preferred embodi 
ment, each fiber in the group at any one place along at least 
about 75% of its length does not deviate more than about 10 
degrees from the central axis of the scaffold. So it is evident 
that this co-alignment aspect does not require 100% precise 
co-alignment of all fibers. The longitudinal co-alignment 
aspect also allows for some minor deviation of specific 
segments of individual fibers to an orientation outside these 
25, 15, and 10 degree requirements. This is reflected in the 
requirement that the longitudinal co-alignment is of each 
fiber along at least 75% of its length, rather than necessarily 
along its entire length. So up to about 25% of the length of 
an individual fiber may be misaligned because, for example, 
it was bent during the scaffold-making process or otherwise. 
Each fiber in the scaffold is not absolutely straight, nor is it 
lying along an absolutely straight line strictly parallel to all 
other fibers in the scaffold. And each fiber is oriented 
generally in the same direction, but each is not oriented in 
exactly the same direction. Moreover, the scaffold itself in 
certain embodiments is curved, bent, or otherwise not 
straight, in which cases the central axis of the scaffold to 
which the alignment of the fibers is within 25 degrees of 
parallel is also curved, bent, or otherwise not straight. In the 
case of a curved scaffold, the fibers must be small enough in 
diameter to be sufficiently flexible to take on a curved 
configuration without breaking. In certain embodiments a 
straight or curved scaffold is machined into a more complex 
shape, in which instance the scaffold central axis refers to the 
central axis as molded and prior to machining. 
In order to allow capillary action and channel-forming, 
the scaffold theoretically contains at least three fibers, 
although the scaffold typically comprises dozens and even 
hundreds of fibers. The fibers lie generally lengthwise of the 
scaffold central axis A (i.e., lie generally in the direction of 
the central axis) and are generally free of helical orientation 
about the scaffold central axis. This arrangement applies to 
at least about 75 vol % of the fibers and preferably to 
substantially all of the fibers. 
The aspect of this embodiment that the fibers are co 
aligned longitudinally contemplates that the fibers are posi 
tioned so that they have a similar alignment, which similar 
alignment may be straight, bent, or curved. In most embodi 
ments they are non-helical. In a separate and distinct aspect 
of certain preferred embodiments, this common alignment is 
limited to a generally straight alignment along at least about 
75%, 85%, or 95% of the length of the fibers. In other words, 
at least about 75%, 85%, or 95% of each fiber is generally 
straight, i.e., at least about 75%, 85%, or 95% of the length 
of each fiber has an alignment which is within 10 degrees of 
a mean straight central axis for the fiber. So up to 5%, 15%, 
or 25% of the length of each fiber may be curved, bent, or 
otherwise deviate more than 10 degrees from straight in 
relation to the overall fiber length, but the rest of each fiber 
is generally straight in that it so deviates less than 10 
degrees. In one preferred embodiment, Substantially the 
entire length of each fiber is generally straight in that it 
deviates less than 10 degrees from the fibers average central 
axis. The “mean straight central axis is the imaginary 
central axis for the fiber which is absolutely straight and is 
an average of all axes along the fiber length. 
The fibers in the scaffold of these embodiments are 
selected to have characteristics suitable for the specific 
application. In one embodiment, the fibers have a length 
between about 2 mm and about 150 mm, such as between 
about 2 and about 20 mm, between about 12 mm and about 
100 mm, or between about 25 mm and about 75 mm. Each 
fiber has a length which is at least about 10 times its 
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diameter. "Diameter as used herein refers to the fiber's 
largest dimension transverse to its length, and it does not 
imply that the fibers are perfectly circular in cross section. 
Each fiber therefore has a fiber lengthwise dimension which 
is at least about 10 times the fiber transverse dimension, e.g., 
diameter. In one embodiment, the fiber length is selected so 
that all, substantially all, or at least about 85 vol% of the 
individual fibers extend the entire length of the scaffold. The 
fibers may be selected to have a pre-molding, pre-joining 
length which corresponds to the length of the scaffold. Or in 
most embodiments, the length of the fibers is longer than the 
desired ultimate scaffold length, and the scaffold is cut to the 
desired length after molding and joining. In an alternative 
embodiment, the length of a Substantial portion (e.g., at least 
40 vol%) or all of the fibers is significantly less than the 
entire length of the scaffold. 
The scaffold in these embodiments is manufactured to 
have a sufficiently high open and interconnected porosity 
from end to end of the scaffold to facilitate capillary flow of 
fluids such as bodily fluids and medicines and components 
they carry through the length of the scaffold, as well as 
generally transverse from outside walls of the scaffold into 
the scaffold interior in directions generally transverse to the 
longitudinal dimension of the fibers. And the scaffold is 
manufactured so that the ultimate porosity is low enough 
that the scaffold has the required strength for handling, 
implantation, and service after implantation. If the porosity 
is too high, the scaffold risks breakage in service, depending 
on where it is implanted and the loads it encounters. In a 
preferred embodiment, the porosity as measured in Volume 
is between about 10% and about 35%, for example between 












25%. The porosity is controllable mainly by controlling the 
degree of softening of the fibers during thermal treatment, in 
that highly softened fibers fuse together more completely to 
a structure with lower porosity. The degree of softening and 
fusing is controlled by controlling the bonding temperature 
and time. Porosity is also affected by the fiber diameter and 
by the range in fiber diameter within a given scaffold. 
Porosity tends to increase with an increasing range in fiber 
diameter. 
The biocompatible material may be glassy, glass ceramic, 
or ceramic in nature. However the glassy state is preferred 
in this invention because, generally speaking, glassy mate 
rials are easier to form into different shapes, bond at lower 
temperatures and are more chemically homogeneous than 
their crystalline or partially crystalline counterparts of the 
same composition. It is therefore preferable that the bio 
compatible material is Substantially glass in that less than 
about 5 wt %, more preferable less than 1 wt %, of the 
component material is crystalline material. More particu 
larly, it is preferable that there is less than 5 wt %, preferably 
less than 1 wt %, crystallization when the material is heated 
to a temperature needed to bond the individual glass par 
ticles together. By way of example, in one embodiment it is 







1 wt %, crystallization when the material is heated to 800° 
C. at an average heating rate of 20° C./min, held at that 
temperature for 10 minutes, then cooled to room tempera 
ture by exposure to STP conditions of room temperature and 
atmospheric pressure. More preferably, the glass will con 
tain less than 5 wt % crystallization, even more preferably 
less than 1 wt % crystallization, after being heated to 575° 
C. with a ramp rate of 20° C./min, and held at that tem 
perature for 20 minutes, then cooled to room temperature by 
exposure to STP conditions. The fibers used in many 
embodiments of the invention, consistent with the foregoing 
description, are at least 99 wt % an amorphous or non 
crystalline solid, for example made by fusing a mixture of 
oxides such as one or more of SiO, BO, POs (known as 
glass forming oxides) with basic oxides such as the alkali 
and alkaline earth oxides, along with the director element. In 
an alternative embodiment, the fibers include glass ceramics 
fibers that contain both glassy and crystalline regions which 
in many respects function in the same manner as a fiber that 
is completely (100%) non-crystalline. It is acceptable in 
Some applications if the glass fiber crystallizes during the 
bonding step. Some of the fibers may alternatively be 
pre-reacted prior to bonding for the purpose of forming a 
thin surface layer of different chemical composition, for 
example, a deakalized layer, or a thin layer of hydroxyapa 
tite or other biologically useful Substance (tricalcium phos 
phate, octacalcium phosphate, dihydrogen calcium phos 
phate). 
Example 1 
Several glasses were prepared with the following com 
positions: 
SiO2 Na2O CaO KO MgO POs CuO SrO ZnO Fe2O. 
6.OO 20.OO 12.OO SOO 4.OO 
S.98. 19.92 11.9S 4.98 3.98 0.40 
5.86 19.52 11.71 4.88 3.90 O.40 2.00 
5.8O 1932 11.59 4.83 386 O.40 2.OO 1.OO 
576. 19.2O 1152 4.8O 384 O.40 2.OO 100 0.40 
SO.88 5.76 19.2O 1152 4.80 3.84 0.40 2.OO 100 0.40 
Scaffolds were prepared from glasses B3 Cu-3, B3 CS, B3 
CSZ, and B3 CSZF. Continuous fibers of these glasses were 
broken into lengths of two to three millimeters (FIG. 1A), 
placed in a ceramic mold in a random fashion, and heated to 
575°C. for 45 minutes to bond the fibers into rigid scaffolds 
as shown in FIG. 1B. After heating, the molds were removed 
from the furnace, and cooled to room temperature. Once at 
room temperature, the scaffolds were removed from the 
molds and ready for use. An example of a scaffold is shown 
in FIG. 1C. The scaffolds were 2 mm thick and 7 mm in 
diameter, and weighed ~70 mg. 
Example 2 
Five scaffolds of each glass were seeded with mesenchy 
mal stem cells, and five were unseeded. The scaffolds were 
implanted into one of four possible locations in the Subcu 
taneous tissue of Fisher 344 rats having an age between 9 
and 11 weeks and a weight between 200 and 300 grams as 
shown in FIG. 2 for six weeks. A scaffold was placed above 
each of the front shoulders and above both hind legs as 
indicated. The cut made in the skin shown by the horizontal 
lines was approximately 20 mm wide and the pocket made 
under the skin (dotted line) is about 20 mm long. The dashed 
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line represents the spine as a reference. Representative 
images of the appearance of each scaffold upon extraction 
are shown in FIG. 3. Soft tissue had infiltrated into each 
scaffold and significant vascular growth had occurred. 
Example 3 
A scaffold of each type was x-rayed after removal from 
the rats to identify any crystalline phases formed while in the 
animal. The XRD patterns for each scaffold are shown in 10 
FIG. 4. The B3 Cu-3 and B3 CS glasses reacted with bodily 
fluids to form hydroxyapatite (Caio (PO4)(OH)), although 
the hydroxyapatite was not necessarily stoichiometric. The 
XRD peaks are smaller in the pattern for the Cu-3 glass than 
those in the pattern for the 13-93B3 glass because the 15 
addition of copper slowed the HA formation kinetics, and 
since the crystals may still be in the process of fully 
crystallizing, the crystals are Smaller and therefore less 
detectable, or possibly a combination. Either way, it is 
significant that the Cu-3 glass formed a material that when 20 
X-rayed had HA peaks of lower intensity than those for the 
13-93B3 glass. Raman spectroscopy of reacted B3 Cu-3 and 
B3 CS fibers as discussed further below indicated that a 
carbonated form of hydroxyapatite known as HCA was 
present. The B3 CSZ glass reacted to form what appeared to 25 
be a multi-phase mixture of hydroxyapatite and calcium 
carbonate (calcite). The XRD patterns of the reacted B3 
CSZF scaffolds contained larger peaks for calcite only. This 
is believed to be the first documented instance known to the 
inventors where any type of a calcium-containing glass 30 
implanted in an animal has reacted to form calcite or any 
other material other than HA/HCA. 
Example 4 
35 
Cross sections of the various scaffolds after removal were 
prepared and examined. FIG. 5 is an SEMBSE image of the 
B3 Cu-3 scaffold (borate glass doped with Cu) after six 
weeks in Subcutaneous tissue. All of the as-made borate 
glass fibers have reacted with the bodily fluids to form 40 
hydroxyapatite, see FIG. 4, and as a consequence, most of 
the fibers have become partially excavated. The hollowing 
effect is caused by the glass containing too little calcium to 
form enough hydroxyapatite upon reaction with the phos 
phate present in the bodily fluids to form a solid fiber. A 45 
similar reaction product, hydroxyapatite, is present in the 
SEMBSE of the borate B3 CS glass (doped with Cuplus Sr) 
in FIG. 6 and the reacted fibers are again mostly hollow. A 
reacted fiber from the B3 CS scaffold was chosen for 
compositional analysis, and is shown in FIG. 7. The chemi- 50 
cal composition was measured at the three numbered spots 
across the fiber in FIG. 7, and SEMEDS spectra generated 
for analysis. The Ca/P molar ratio of the material at the three 
numbered spots is shown in the figure. Except for trace 
amounts of Na, Mg, and K; Ca and P were the major 55 
components at each spot and the similarity in the peak height 
for each in the spectra revealed that the chemical composi 
tion of the reacted fiber is similar from the center (point 3) 
to the outer surface (point 1). The XRD data in FIG. 4 
indicate that the initially glass fibers had converted to HA. 60 
The SEMBSE image of a scaffold made from B3 CSZ 
fibers (doped with Cu, Sr., and Zn), is shown in FIG. 8. Some 
of the larger diameter fibers in the lower left side of the 
image, which have a white material in the center have not 
fully reacted with the bodily fluids. The white core is 65 
composed of the unreacted B3 CSZ glass. The fibers at the 
outer edge of the scaffold (right center and side) are fully 
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reacted but not hollow as were the B3 Cu-3 and B3 CS 
fibers. A relatively small region of a calcium containing 
material is present at the center of the B3 CSZ fibers. This 
is better illustrated by the fiber in FIG.9, where three distinct 
layers of material are visible. The composition at the four 
numbered spots across the fiber was measured by SEMEDS. 
At spot 1 (center) only calcium and oxygen were detected 
along with trace amounts of Mg, and K. Carbon may have 
been present, but is undetectable by SEMEDS, so this 
material is consistent with being CaCO as found by XRD, 
see FIG. 4. The SEMEDS spectra at spots 2 and 3 contained 
peaks for both calcium and phosphorus with an intensity 
ratio similar to that of hydroxyapatite. Spot 4 (at the outer 
edge) contained both calcium and phosphorus and had the 
highest signal among spots 2, 3, and 4. The SEMEDS and 
XRD results indicate that a relatively dense layer of HA at 
the outer Surface (spot 4) surrounds a more porous and 
layered hydroxyapatite-like material at spots 3 and 2, and the 
white, calcium rich, material at the core, spot 1, is most 
likely calcium carbonate (calcite). 
The SEMBSE image in FIG. 10 of the B3 CSZF scaffold, 
made from fibers doped with Cu, Sr., Zn and Fe shows a 
cross section of reacted fibers with a hydroxyapatite outer 
layer and a calcium-rich core (lighter material) similar to 
that shown for the B3 CSZ scaffold in FIG.8. The image in 
FIG. 10 however shows there is significantly more calcium 
present within the reacted fibers than in FIG. 8. The larger 
amounts of calcium present in the B3 CSZF scaffold are 
evident both visually in the SEM images in FIGS. 8 and 10 
and by the height (size) of the peaks in the XRD patterns in 
FIG. 4 which provide a positive identification that the 
material is calcium carbonate, calcite. Verification that the 
calcium-rich core in the B3 CSZF glass was calcite and free 
of phosphate is provided by the SEM phase map for the 
reacted B3 CSZF fiber, shown in FIG. 11. Calcium is present 
throughout the fiber, in what is believed to be hydroxyapa 
tite-like material and presumably calcium carbonate. How 
ever, the largest concentration of calcium is at the core as 
indicated by the bright spot in the upper left of FIG. 11. 
There are only low levels of Mg, Sr., and K in the fiber 
indicating that the glass has significantly reacted and most of 
the elements have been released to the bodily fluids. Phos 
phorus is present in the outer portions of the fiber but there 
is a distinct area devoid of phosphorus in the center of the 
fiber at the same area of highest calcium concentration, 
which means there is no calcium phosphate present. SEM 
EDS at four spots across the same fiber in FIG. 12 show a 
similar reaction product as that present in the B3 CSZ fibers. 
There is a thin outer layer (1-2 micron) of dense hydroxy 
apatite (spot 4), a region of porous and layered hydroxy 
apatite (spots 2 and 3), and a calcium rich core (spot 1) as 
indicated by the relative intensity of the SEMEDS peaks. 
The fiber reacted with bodily fluids and formed a distinctly 
different material at the center (white). The Ca/P molar ratio 
was measured with SEMEDS at the four numbered spots 
indicated. As shown in FIG. 13, at higher magnification, the 
reacted calcium-rich core (white center) had a similar lay 
ered structure as that of the Surrounding hydroxyapatite, 
which is formed as the glass reacts with bodily fluids. The 
reaction of the borate glass fibers with the bodily fluids starts 
at the external surface of the fiber and proceeds inward. 
Example 5 
To determine the role the minor director elements played 
in the conversion reaction of the scaffolds, X-ray fluores 
cence (XRF) was used to measure the composition of the 
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as-made glass and the scaffolds reacted in vivo. The as-made 
glass was measured to verify the presence of the minor 
elements in the as-made glass, and to ensure the relative 
concentrations of the minor elements were similar. The XRF 
patterns for the minor elements of interest (Cu, Sr., Zn, and 
Fe) for the fourglasses are shown in FIGS. 14A and 14B. All 
four minor elements (Cu, Sr., Zn, and Fe) were present in the 
as-made glasses (prior to implantation). The concentrations 
of Cu were similar in all four of the as-made glasses as 
expected, and the Zn concentration was essentially identical 
in the two glasses to which it was added. The arrow in 14A 
indicates a peak associated with the polymer mounting 
material. A scaffold of each type seeded with mesenchymal 
stem cells was analyzed to determine if the minor elements 
(Cu, Sr., Zn and Fe) were detectable in the scaffold of soft 
tissue after the in vivo reaction. The XRF patterns shown in 
FIGS. 15A and 15B are for scaffolds after six weeks in vivo, 
and all four minor elements were detected in either the 
reacted fibers or the new soft tissue. The Sr was weakly 
detectable in the HA layers from the SEMEDS phase map in 
FIG. 11; but the other minor elements (Cu, Zn,Fe) were of 
too low concentration to determine if they were present in 
the HA layer by SEMEDS. The arrow in 15A indicates a 
peak associated with the polymer mounting material. The 
XRF data in FIGS. 15A and 15B proves that at least some 
of the minor elements were present in the reacted scaffold or 
soft tissue adjacent to the fibers and not completely removed 
by bodily fluids, which may explain why the fibers reacted 
differently and calcium carbonate instead of HA was formed 
in the B3 CSZ and B3 CSZF fibers. 
The contrast in color, or shading, of the SEMBSE images 
between the B3 CS fiber and the B3 CSZF fiber along with 
the hollow nature of the B3 Cu-3 and B3 CS fiber versus the 
partially filled B3 CSZ and B3 CSZF fibers, with a calcium 
rich core, points to a change in how the glasses react with the 
bodily fluids and how calcium is potentially blocked from 
reacting with the phosphate in the bodily fluids. The hollow 
core of a reacted fiber or particle has been previously 
described as what occurs in a glass which does not contain 
enough calcium to form a fully dense structure composed of 
HA. The B3 CS and B3 CSZF glasses had an almost 
identical amount of calcium present and formed completely 
different structures when they reacted in vivo in an identical 
environment. The combination of minor elements with those 
already present in the glass caused a change in the bonding 
between the calcium and phosphorus which made a more 
porous structure of hydroxyapatite followed by the deposit 
of a calcium rich core. 
With additional compositional modifications, it should be 
possible to completely block the formation of hydroxyapa 
tite and form other calcium containing compounds (phos 
phates, carbonates, hydrates, fluorides, etc.). Other combi 
nations of minor elements may make it possible to form 
compounds other than hydroxyapatite or calcium carbonate, 
and make new multicomponent reaction products similar to 
those described above. Mixing fibers of different composi 
tions that form different reaction products as a blended 
scaffold offers a way to make an entirely new family of 
degradable materials that are biocompatible. These reaction 
products are potentially useful in drug delivery or bone or 
other soft tissue regeneration. 
Example 6 
A silicate based bioactive glass 13-93 was modified 
similarly to that of 93B3 glass by adding small amounts of 













in the foregoing table. The glass was melted, plate quenched, 
and crushed to a particle size range of 150 to 300 microns. 
The particles were immersed in simulated bodily fluid for up 
to 2 weeks at 37° C. and x-rayed for phase identification. 
After 1 week in simulated bodily fluids, relatively broad 
XRD peaks were present as shown by the bottom pattern in 
FIG. 16, but no crystalline phases could be identified. In the 
XRD pattern at 2 weeks (middle pattern in FIG. 16) Small, 
barely detectable XRD peaks corresponding to HA (black 
arrows) were present when compared to the top pattern 
above which is for a bioactive borate glass reacted in vivo. 
The large peaks at ~24 and 31 degrees 20 are not associated 
with HA, but match well with CaSiO. There are several 
other smaller peaks that match the standard XRD pattern for 
CaSiO, and those peaks are indicated by the arrows in FIG. 
16. Assuming the four minor elements in the glass prevent 
the formation of calcium with phosphate to form a HA type 
phase as in the borate glasses described earlier, the calcium 
would be free to bond with the silica to form a calcium 
silicate compound Such as Ca2SiO4. The formation of a 
material other than HA in a bioactive silicate glass is 
important because this means that the addition of minor 
elements can be used in either silicate or borate glasses to 
control or alter the reaction products that form when in 
contact with bodily fluids or simulated bodily fluids and 
different materials having desired properties can be made on 
demand by this method of adding minor elements. 
Example 7 
Micro Raman analysis was performed on glasses of the 
invention and glasses not of the invention to investigate 
what compounds are formed in vivo. 
A reacted 13-93B3 fiber of the composition described in 
Example 1 (reacted four weeks in vivo) was analyzed by 
micro raman at four locations, and the micro-raman spectra 
for the four spots are shown in FIG. 17. Spot one is located 
at the outer edge of the fiber and spot four at the center of 
the reacted fiber. The peaks associated with HA (431 cm 
(PO, v2),965 cm (PO, v1), 1065 to 1070 cm (CO, 
v1) and 1076 cm PO, v3) are denoted by dashed lines. 
The solid lines indicate peaks due to the PMMA mounting 
medium as demonstrated by the spectrum shown at the top 
of FIG. 17. 
Spots three and four located near the center of the reacted 
13-93B3 fiber have the highest intensities for the phosphate 
and carbonate peaks of the four spots analyzed, indicating 
there may be a difference in the amount of each species 
distributed throughout the reacted layers. The difference in 
the measured amount of phosphate and carbonate measured 
could also be due to density differences of the reacted fiber, 
especially at the center with the layered microstructure. The 
difference in the phosphate and carbonate concentration may 
also indicate that the fiber is not completely converted. The 
presence of a carbonate peak at 1065 to 1070 cm (CO’ 
V 1) indicates that the reacted fibers are carbonated, similar 
to natural bone. The significance of this analysis is the 
presence of hydroxyapatite and the absence of calcite in this 
prior art glass containing borate as the primary glass former, 
and also containing Na2O, CaO, K2O, MgO, and POs. 
Micro Raman analysis of a Cu-3 fiber (Example 1) after 
six weeks in vivo was performed at seven spots across the 
cross section of a reacted fiber from its outer edge to its 
center. See FIG. 18. The majority of the peaks in the Raman 
spectra are due to the PMMA in which the scaffold is 
mounted. The peaks important for identifying HA are 
located at 431 cm (PO, v2), 965 cm (PO. v1), 1065 
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cm and 1070 cm (CO, v1), and 1078 cm (PO, v3). 
The intensity of the HA peaks in spectra one to five are 
almost identical indicating no significant change in the 
material from the outer edge to the center. The PO, V2 and 
PO, v3 peaks in spectra six are noticeably lower than the 
corresponding peaks in spectra one to five. There was also 
an increase in the intensity of the PMMA peak at 600 cm 
in spectra six indicating a higher porosity of the fiber at its 
center. The presence of CO, peaks are the first evidence 
that the HA is carbonated similar to natural bone. 
FIG. 19 shows micro Raman spectra of a CS fiber 
(Example 1) after six weeks in vivo at five spots across the 
fiber from its outer edge to its center. The only peaks 
associated with HA are located at 428 cm (PO, V2) and 
the broad peak at 1065-1080 which encompasses 1065 and 
1070 cm (CO, v1), and 1078 cm (PO, v3). The 965 
cm (PO, V1) peak for HA was not seen in any of the 
spectra in FIG. 19. 
FIG. 20 shows the ten spots analyzed by micro Raman 
spectroscopy of a CSZ fiber (Example 1) after six weeks in 
vivo from its outer edge to its center. The first five spectra 
in FIG. 21 are from the outer edge to up to the interface 
between the porous calcium phosphate and the calcium rich 
center. No peaks associated with HA are present in the micro 
Raman spectra for spots one to five. The spectra for the 
calcium rich center in FIG.22 contain two peaks at 711 cm 
and 1085 cm in spectra 6 to 10 and these peaks are 
associated with calcium carbonate in the form of calcite. 
FIG. 23 shows the six spots analyzed by micro Raman 
spectroscopy for a CSZF fiber (Example 1) after six weeks 
in vivo, from its outer edge to its center. No peaks associated 
with HA were present in any spots analyzed. The peaks at 
711 cm and 1085 cm, attributable to calcite, were present 
once inside the calcium rich center at spots four to six. 
In summary, analysis of the reacted fibers showed that the 
majority of un-doped fibers were fully converted to 
hydroxyapatite after four weeks. The addition of the minor 
elements affected the conversion of the bioactive glass 
scaffolds to hydroxyapatite. The scaffold containing copper 
converted to HA, but a slower rate than the base glass 
without copper. The combination of copper and strontium 
significantly retarded the reaction of the phosphate in the 
bodily fluids with the calcium released from the borate glass 
as determined by micro Raman measurements, but a highly 
porous HA had formed instead according to XRD. The 
addition of Zinc to the copper and strontium doped borate 
glass effectively stopped the formation of calcium phosphate 
(HA) toward the center of the fibers and formed calcium 
carbonate in the form of calcite formed instead. When iron 
was added to a glass doped with copper, strontium, and Zinc 
the formation of calcium phosphate (HA) was decreased 
even further as the calcite present at the center of the reacted 
fibers continued to increase. This is believed to be the first 
time calcium containing bioactive glasses were documented 
to transform to materials other than calcium phosphates in 
vivo. 
The foregoing data show a progressive change in the 
reaction of borate glasses with the bodily fluids of a rat. With 
the addition of the minor elements, such as Cu, Sr., Zn, and 
Fe, to a borate glass, the formation of HA ceases and 
eventually only calcium carbonate is formed. The elements 
that had the largest effect on the conversion of the glass to 
HA were zinc and iron. The XRD first peaks for calcite 
appeared in the CSZ (Ca,Sr., Zn) scaffold, and when a small 
amount of Fe was added to that composition, HA could not 














As noted above, calcium-containing implantable bioac 
tive glasses form hydroxyapatite upon reaction with bodily 
fluids. In accordance with this invention, the glass compo 
sition is formulated to include the one or more director 
elements so as to produce calcium compounds other than 
hydroxyapatite. In some embodiments, these other calcium 
compounds are formed entirely instead of hydroxyapatite. In 
other embodiments, a mixture of hydroxyapatite and one or 
more other calcium-based compounds is formed. In one 
preferred embodiment of the invention, the implantable 
glass composition is formulated to promote the formation of 
calcite upon reaction with bodily fluids in vivo. Without 
being bound to a particular theory, it appears the ionic radius 
of a particular element has an impact on its efficacy as a 
director element alone or in combination with other ele 
ments in accordance with this invention. In particular, it is 
believed that an element with a relatively smaller ionic 
radius Such as less than about 1 angstrom, or on the order of 
0.8 angstroms or less, provides moderate to severe inhibition 
of hydroxyapatite formation, and biases the system toward 
calcite formation. FIG. 24 is a schematic graph showing 
relative inhibition of hydroxyapatite in the presence of six 
coordinated ions in aqueous environments. 
Calcite is a polymorph of calcium carbonate that can be 
found in nature in both seashells and coral. Calcite has been 
used as a degradable scaffold material and has been shown 
to promote bone marrow induced osteogenesis better than a 
comparable hydroxyapatite scaffold. Calcite has been 
reported to remodel at a faster rate than natural or synthetic 
HA and tricalcium phosphate through in vitro osteoclast 
excavation experiments. Bone cement filled with calcite 
powder has also been made for biomedical use. Accordingly, 
the discovery herein of the ability to form calcite in vivo 
with implantable glass compositions, and to reduce, mini 
mize, and/or eliminate HA formation, presents a significant 
advancement in treatment opportunities. 
When introducing elements of the present invention or the 
preferred embodiments(s) thereof, the articles “a”, “an', 
“the' and “said are intended to mean that there are one or 
more of the elements. The terms “comprising”, “including 
and “having are intended to be inclusive and mean that 
there may be additional elements other than the listed 
elements. 
As various changes could be made in the above compo 
sitions and methods without departing from the scope of the 
invention, it is intended that all matter contained in the 
above description and shown in the accompanying drawings 
shall be interpreted as illustrative and not in a limiting sense. 
The invention claimed is: 
1. A biocompatible composition for tissue repair or regen 
eration in mammals comprising: 
40 to 80 wt % B.O.; 
2.5 to 50 wt % CaO; 
one or more of MgO, SrO, and combinations thereof in a 
cumulative concentration of 5 to 40 wt %; 
one or more of LiO, NaO, KO, Rb2O and combinations 
thereof; 
one or more director elements selected from the group 
consisting of Cu, Zn, Fe, Mn, Ba, Co., S. V. and/or Y in 
a cumulative concentration between 0.05 and 5 wt % to 
promote in Vivo calcium compound formation of cal 
cium carbonate or other calcium-containing materials 
other than hydroxyapatite; 
wherein upon direct application of the biocompatible 
composition to a mammalian host, calcium carbonate 
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or other calcium-containing materials other than 
hydroxyapatite form upon bioreaction of the composi 
tion with bodily fluids; 
wherein the composition is in a form of one or more of 
fibers, hollow fibers, tubes, ribbons, solid spheres, 5 
hollow spheres, particles, bonded particles, and com 
binations thereof assembled in a scaffold which has a 
porosity of between about 15 and about 90 vol% with 
at least about 75 vol% of pores being interconnected 
and Suitable for application to a mammalian host Such 
that it is exposed to the mammalian host’s bodily fluids 
for tissue repair or regeneration in mammals; and 
wherein the composition is not water soluble. 
2. The biocompatible composition of claim 1 wherein said 
calcium carbonate or other calcium-containing materials 
other than hydroxyapatite that forms upon bioreaction of the 
composition with bodily fluids comprises calcite; and 
wherein hydroxyapatite also forms upon bioreaction of 
the composition with bodily fluids. 2O 
3. The biocompatible composition of claim 1 wherein 
hydroxyapatite does not form upon bioreaction of the com 
position with bodily fluids. 
4. The biocompatible composition of claim 3 wherein the 
director element is selected from the group consisting of Cu, 25 
Zn, Fe, Mn, Ba, Co, and/or S. 
5. The biocompatible composition of claim 3 wherein the 
director element is selected from the group consisting of Cu, 
Mn, Ba, Co, and/or S. 
6. The biocompatible composition of claim 3 wherein the 
director element is Zn and/or Fe. 
7. The biocompatible composition of claim 1 comprising, 
approximately: 
40 to 80 wt % BO 
1 to 25 wt % NaO 
1 to 25% KO 
5 to 40 wit 9% CaO 
1 to 25 wt % MgO 
1 to 10 wt % POs 40 
said one or more director elements; 
said one or more of LiO, Rb2O, SiO, Al-O, and F. 
8. The biocompatible composition of claim 1 consisting of 
approximately: 
40 to 80 wt % BO 45 
1 to 25 wt % NaO 
1 to 25% KO 
5 to 40 wit 9% CaO 
1 to 25 wt % MgO 
1 to 10 wt % POs 50 
and said one or more director elements, 
one or more of LiO, Rb2O, SiO, Al-O, and F. 
9. The biocompatible composition of claim 1 comprising, 
approximately: 
40 to 80 wt % BO 55 
1 to 25 wt % NaO 
1 to 25% KO 
12 to 24 wt % CaO 
1 to 25 wt % MgO 
1 to 10 wt % POs 60 
O.1 to 2.5 wt % CuO. 
10. The biocompatible composition of claim 1 compris 
ing, approximately: 
40 to 80 wt % BO 
1 to 25 wt % NaO 65 
1 to 25% KO 






1 to 25 wt % MgO 
1 to 10 wt % POs 
O.1 to 2.5 wt % CuO. 
11. The biocompatible composition of claim 1 compris 
ing, approximately: 
40 to 80 wt % BO, 
1 to 25 wt % NaO 
1 to 25% KO 
5 to 40 wit 9% CaO 
1 to 25 wt % MgO 
1 to 10 wt % POs 
O.1 to 2.5 wt % CuO 
O.1 to 2.5 wt % ZnO. 
12. The biocompatible composition of claim 1 compris 
ing, approximately: 
40 to 80 wt % BO, 
1 to 25 wt % NaO 
1 to 25% KO 
5 to 40 wit 9% CaO 
1 to 25 wt % MgO 
1 to 10 wt % POs 
O.1 to 2.5 wt % CuO 
O.1 to 2.5 wt % ZnO 
0.1 to 2.5 wt % Fe...O. 
wherein the one or more director elements is supplied by 
said CuO, ZnO, and/or FeO. 
13. A biocompatible composition for tissue repair or 
regeneration in mammals comprising, approximately: 
40 to 80 wt % BO, 
1 to 25 wt % NaO 
1 to 25% KO 
5 to 40 wit 9% CaO 
1 to 25 wt % MgO 
1 to 10 wt % P.O. 
one or more director elements selected from the group 
consisting of Cu, Zn, Fe, Mn, Ba, Co., S. V. and/or Y in 
a cumulative concentration between 0.05 and 5 wt % to 
promote in Vivo calcium compound formation of cal 
cium carbonate or other calcium-containing materials 
other than hydroxyapatite; 
optionally one or more of LiO, Rb2O, SiO, Al-O, and 
F; 
wherein the composition is in the form of a scaffold of 
glass fibers; 
wherein the scaffold has a porosity of between about 15 
and about 90 vol % with at least about 75 vol% of 
pores being interconnected; 
wherein the glass fibers have lengths between about 2 and 
about 150 mm and a length:diameter aspect ratio of at 
least 5:1; 
wherein the composition is not water soluble. 
14. The biocompatible composition of claim 3 wherein 
the composition comprises from 10 to 90 wt % of compo 
nents having one composition and from 10 to 90 wt % of 
components of a different composition. 
15. The biocompatible composition of claim 3 wherein 
the composition is in the form of fibers and spheres. 
16. The biocompatible composition of claim 1 wherein 
the one or more director elements are Zn and Fe. 
17. The biocompatible composition of claim 1 wherein 
the one or more director elements is Zn. 
18. The biocompatible composition of claim 1 wherein 
the one or more director elements is Fe. 
US 9,561,303 B2 
29 
19. The composition of claim 1 comprising fibers having 
a diameter between 20 and 5000 microns. 
20. The composition of claim 1 comprising fibers having 
a diameter between 100 and 300 microns. 
21. The composition of claim 1 comprising particles 5 
having a particle size in the range of 150 to 300 microns. 
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